We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+79.02%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$281M
Cap. Flow
-$93.3M
Cap. Flow %
-6.73%
Top 10 Hldgs %
66.46%
Holding
81
New
10
Increased
14
Reduced
17
Closed
22

Top Buys

Rank Stock Value
1
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$37.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
3
MRK icon
Merck
MRK
+$20.7M
4
BIIB icon
Biogen
BIIB
+$17.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.7M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$26.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
4
AGN
Allergan plc
AGN
+$22.6M
5
AMGN icon
Amgen
AMGN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 94.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
51
KALA BIO
KALA
$11.8M
$2.45M 0.18%
266
+75
+39% +$724K
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$1.52M 0.11%
49,580
– –
SYBX
53
DELISTED
Synlogic
SYBX
$1.48M 0.11%
38,331
– –
QTTB icon
54
Q32 Bio
QTTB
$450M
$1.33M 0.1%
3,578
-4,550
-56% -$1.3M
HALO icon
55
Halozyme
HALO
$9.72B
$1.28M 0.09%
72,481
-563,686
-89% -$9.76M
HRTX icon
56
Heron Therapeutics
HRTX
$86.3M
$1.19M 0.09%
50,500
-53,102
-51% -$1.17M
RYTM icon
57
Rhythm Pharmaceuticals
RYTM
$7B
$489K 0.04%
+21,319
New +$474K
PDSB icon
58
PDS Biotechnology
PDSB
$38.1M
$378K 0.03%
142,635
– –
AKBA icon
59
Akebia Therapeutics
AKBA
$327M
– –
-1,227,191
Closed -$4.81M
ALGN icon
60
Align Technology
ALGN
$12B
– –
-10,000
Closed -$1.81M
AMGN icon
61
Amgen
AMGN
$203B
– –
-92,300
Closed -$17.9M
BMY icon
62
Bristol-Myers Squibb
BMY
$127B
– –
-478,349
Closed -$24.3M
CYTK icon
63
Cytokinetics
CYTK
$11B
– –
-210,992
Closed -$2.4M
HRTX icon
64
CALL
Heron Therapeutics
HRTX
$86.3M
– –
-177,200
Closed -$3.28M
NBIX icon
65
Neurocrine Biosciences
NBIX
$17.7B
– –
-191,679
Closed -$17.3M
PFE icon
66
Pfizer
PFE
$140B
– –
-432,780
Closed -$14.8M
SNDX icon
67
CALL
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-100,000
Closed -$746K
SNDX icon
68
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-243,150
Closed -$1.82M
SNDX icon
69
PUT
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-200,000
Closed -$1.49M
SVRA icon
70
Savara
SVRA
$1.13B
– –
-527,318
Closed -$1.4M
XLB icon
71
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.51B
– –
-600,000
Closed -$27M
ONC
72
CALL
BeOne Medicines Ltd
ONC
$33.8B
– –
-50,000
Closed -$6.12M
VIRX
73
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-32,398
Closed -$816K
RETA
74
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-148,669
Closed -$11.9M
RETA
75
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-148,600
Closed -$11.9M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Sofinnova Investments held 81 positions worth $1.39B, up 25% from $1.11B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $93.3M in Q4 2019, closing 22 positions and reducing 17 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $46.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 88% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Galera Therapeutics, Inc. Common Stock worth $40.6M.

  • Sofinnova Investments's largest Q4 2019 buy was Galera Therapeutics, Inc. Common Stock: 3,083,712 shares worth $40.6M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q4 2019, an estimated $27M increase.
  • Sofinnova Investments's biggest Q4 2019 reduction was Acceleron Pharma, cutting an estimated $11.9M.
  • Sofinnova Investments fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $46.7M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.39B portfolio in Q4 2019.
  • Sofinnova Investments opened 10 new positions and closed 22 in Q4 2019.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.39B.

Based on Sofinnova Investments's 13F filing for Q4 2019, filed 14 Feb 2020.